Patents by Inventor Steven August SMITH

Steven August SMITH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosing of a Bruton's tyrosine kinase inhibitor
    Patent number: 12551463
    Abstract: The present invention provides a method of administering doses of the BTK inhibitor, (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide or a pharmaceutically acceptable salt thereof for use in treating conditions such as cancer and autoimmune diseases.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: February 17, 2026
    Assignee: LOXO ONCOLOGY, INC.
    Inventors: Barbara Jean Brandhuber, Nora Chien Yee Ku, Nisha Nanda, Steven August Smith, Donald Tsai
  • THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2 ARYLBENZIMIDAZOLE
    Publication number: 20250281462
    Abstract: Methods are provided for reducing neuroinflammation and/or treating a neurodegenerative disease in a subject. The methods comprise orally administering to a subject with neuroinflammation and/or a neurogenerative disease a pharmaceutical composition comprising the compound of formula (I) (TQS-168), or a pharmaceutically acceptable salt thereof, in amount that provides defined plasma and brain exposures of TQS-168 and/or an active metabolite following administration.
    Type: Application
    Filed: January 13, 2025
    Publication date: September 11, 2025
    Inventors: Jonas O'Gara HANNESTAD, Steven August SMITH, Sanjay Kumar KAKKAR
  • THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2 ARYLBENZIMIDAZOLE
    Publication number: 20240307356
    Abstract: Methods are provided for reducing neuroinflammation and/or treating a neurodegenerative disease in a subject. The methods comprise orally administering to a subject with neuroinflammation and/or a neurogenerative disease a pharmaceutical composition comprising the compound of formula (I) (TQS-168), or a pharmaceutically acceptable salt thereof, in amount that provides defined plasma and brain exposures of TQS-168 and/or an active metabolite following administration.
    Type: Application
    Filed: June 17, 2022
    Publication date: September 19, 2024
    Inventors: Jonas O'Gara HANNESTAD, Steven August SMITH, Sanjay Kumar KAKKAR
  • DOSING OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20230041515
    Abstract: The present invention provides a method of administering doses of the BTK inhibitor, (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide or a pharmaceutically acceptable salt thereof for use in treating conditions such as cancer and autoimmune diseases.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 9, 2023
    Inventors: Barbara Jean BRANDHUBER, Nora Chien Yee KU, Nisha NANDA, Steven August SMITH, Donald TSAI